Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 239

1.

Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia.

Hashimoto K, Fukushima T, Shimizu E, Komatsu N, Watanabe H, Shinoda N, Nakazato M, Kumakiri C, Okada S, Hasegawa H, Imai K, Iyo M.

Arch Gen Psychiatry. 2003 Jun;60(6):572-6.

PMID:
12796220
2.

Possible role of D-serine in the pathophysiology of Alzheimer's disease.

Hashimoto K, Fukushima T, Shimizu E, Okada S, Komatsu N, Okamura N, Koike K, Koizumi H, Kumakiri C, Imai K, Iyo M.

Prog Neuropsychopharmacol Biol Psychiatry. 2004 Mar;28(2):385-8.

PMID:
14751437
3.

Reduced D-serine to total serine ratio in the cerebrospinal fluid of drug naive schizophrenic patients.

Hashimoto K, Engberg G, Shimizu E, Nordin C, Lindström LH, Iyo M.

Prog Neuropsychopharmacol Biol Psychiatry. 2005 Jun;29(5):767-9.

PMID:
15939521
4.

Changes in plasma glycine, L-serine, and D-serine levels in patients with schizophrenia as their clinical symptoms improve: results from the Juntendo University Schizophrenia Projects (JUSP).

Ohnuma T, Sakai Y, Maeshima H, Hatano T, Hanzawa R, Abe S, Kida S, Shibata N, Suzuki T, Arai H.

Prog Neuropsychopharmacol Biol Psychiatry. 2008 Dec 12;32(8):1905-12. doi: 10.1016/j.pnpbp.2008.07.022. Epub 2008 Sep 16.

PMID:
18835577
5.

Identification of multiple serine racemase (SRR) mRNA isoforms and genetic analyses of SRR and DAO in schizophrenia and D-serine levels.

Yamada K, Ohnishi T, Hashimoto K, Ohba H, Iwayama-Shigeno Y, Toyoshima M, Okuno A, Takao H, Toyota T, Minabe Y, Nakamura K, Shimizu E, Itokawa M, Mori N, Iyo M, Yoshikawa T.

Biol Psychiatry. 2005 Jun 15;57(12):1493-503.

PMID:
15953485
6.

D-serine serum levels in patients with schizophrenia: relation to psychopathology and comparison to healthy subjects.

Hons J, Zirko R, Ulrychova M, Cermakova E, Libiger J.

Neuro Endocrinol Lett. 2008 Aug;29(4):485-92.

PMID:
18766161
7.

Glycine serum level in schizophrenia: relation to negative symptoms.

Hons J, Zirko R, Ulrychova M, Cermakova E, Doubek P, Libiger J.

Psychiatry Res. 2010 Apr 30;176(2-3):103-8. doi: 10.1016/j.psychres.2009.11.008. Epub 2010 Jan 22.

PMID:
20096465
8.

D-serine added to antipsychotics for the treatment of schizophrenia.

Tsai G, Yang P, Chung LC, Lange N, Coyle JT.

Biol Psychiatry. 1998 Dec 1;44(11):1081-9.

PMID:
9836012
9.

D-alanine added to antipsychotics for the treatment of schizophrenia.

Tsai GE, Yang P, Chang YC, Chong MY.

Biol Psychiatry. 2006 Feb 1;59(3):230-4. Epub 2005 Sep 9.

PMID:
16154544
10.

A genetic variant of the serine racemase gene is associated with schizophrenia.

Morita Y, Ujike H, Tanaka Y, Otani K, Kishimoto M, Morio A, Kotaka T, Okahisa Y, Matsushita M, Morikawa A, Hamase K, Zaitsu K, Kuroda S.

Biol Psychiatry. 2007 May 15;61(10):1200-3. Epub 2006 Oct 25.

PMID:
17067558
11.

Changes in plasma D-serine, L-serine, and glycine levels in treatment-resistant schizophrenia before and after clozapine treatment.

Yamamori H, Hashimoto R, Fujita Y, Numata S, Yasuda Y, Fujimoto M, Ohi K, Umeda-Yano S, Ito A, Ohmori T, Hashimoto K, Takeda M.

Neurosci Lett. 2014 Oct 17;582:93-8. doi: 10.1016/j.neulet.2014.08.052. Epub 2014 Sep 10.

PMID:
25218715
12.

Different serine and glycine metabolism in patients with schizophrenia receiving clozapine.

Hons J, Vasatova M, Cermakova E, Doubek P, Libiger J.

J Psychiatr Res. 2012 Jun;46(6):811-8. doi: 10.1016/j.jpsychires.2012.03.015. Epub 2012 Apr 13.

PMID:
22502820
13.

A new strategy to decrease N-methyl-D-aspartate (NMDA) receptor coactivation: inhibition of D-serine synthesis by converting serine racemase into an eliminase.

Panizzutti R, De Miranda J, Ribeiro CS, Engelender S, Wolosker H.

Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5294-9. Epub 2001 Apr 17.

14.

Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia.

Tsai G, Lane HY, Yang P, Chong MY, Lange N.

Biol Psychiatry. 2004 Mar 1;55(5):452-6.

PMID:
15023571
15.

Serine racemase protein expression in cortex and hippocampus in schizophrenia.

Steffek AE, Haroutunian V, Meador-Woodruff JH.

Neuroreport. 2006 Jul 31;17(11):1181-5.

PMID:
16837850
16.

Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study.

Lane HY, Chang YC, Liu YC, Chiu CC, Tsai GE.

Arch Gen Psychiatry. 2005 Nov;62(11):1196-204.

PMID:
16275807
17.

The involvement of the NMDA receptor D-serine/glycine site in the pathophysiology and treatment of schizophrenia.

Labrie V, Roder JC.

Neurosci Biobehav Rev. 2010 Mar;34(3):351-72. doi: 10.1016/j.neubiorev.2009.08.002. Epub 2009 Aug 18. Review.

PMID:
19695284
18.

Modulation of D-serine levels via ubiquitin-dependent proteasomal degradation of serine racemase.

Dumin E, Bendikov I, Foltyn VN, Misumi Y, Ikehara Y, Kartvelishvily E, Wolosker H.

J Biol Chem. 2006 Jul 21;281(29):20291-302. Epub 2006 May 19.

19.

[Endogenous D-serine in mammalian brains].

Nishikawa T, Yamamoto N, Tsuchida H, Umino A, Kawaguchi N.

Nihon Shinkei Seishin Yakurigaku Zasshi. 2000 Feb;20(1):33-9. Review. Japanese.

PMID:
10890022
20.

Allosteric modulation of NMDA receptor via elevation of brain glycine and D-serine: the therapeutic potentials for schizophrenia.

Yang CR, Svensson KA.

Pharmacol Ther. 2008 Dec;120(3):317-32. doi: 10.1016/j.pharmthera.2008.08.004. Epub 2008 Aug 27. Review.

PMID:
18805436

Supplemental Content

Support Center